Everest Medicines Limited (HKG:1952)
58.45
+1.65 (2.90%)
Apr 3, 2025, 4:08 PM HKT
Everest Medicines Revenue
In the year 2024, Everest Medicines had annual revenue of 706.68M CNY with 461.16% growth. Everest Medicines had revenue of 405.16M in the half year ending December 31, 2024, with 3,348.77% growth.
Revenue
706.68M CNY
Revenue Growth
+461.16%
P/S Ratio
24.94
Revenue / Employee
1.06M CNY
Employees
665
Market Cap
18.96B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Alibaba Health Information Technology | 31.39B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Everest Medicines News
- 9 days ago - AI-powered Cancer Vaccine In The Works - Benzinga
- 8 months ago - Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Benzinga